Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CLPP | Q16740 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14309433 | 0.93 | CACNA1G (0.41) | MEN1KMT2ATSHRCACNA1GCACNA1H | |
| SCHEMBL13773538 | 0.91 | KMT2A (0.39) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14504752 | 0.90 | CLPP (0.53) | MEN1KMT2ACYP3A4CLPP | |
| SCHEMBL14309463 | 0.90 | KMT2A (0.41) | MEN1KMT2ATSHRCACNA1GCACNA1H | |
| SCHEMBL14319413 | 0.90 | PDE4A (0.40) | MEN1KMT2ACYP3A4CYP2C19RAB9A | |
| SCHEMBL14309871 | 0.89 | MEN1 (0.48) | MEN1KMT2ACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14309868 | 0.89 | MEN1 (0.51) | MEN1KMT2ACYP3A4CACNA1GCACNA1H | |
| SCHEMBL14310175 | 0.88 | CACNA1I (0.42) | MEN1KMT2ACYP3A4CACNA1GCACNA1H | |
| SCHEMBL14504312 | 0.88 | ALDH1A1 (0.40) | MEN1KMT2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL13773612 | 0.88 | MEN1 (0.47) | MEN1KMT2ACYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | INSTITUTE FOR CHEMICAL GENOMICS | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | COL1A1, COL2A1, PLOD3 | MEN1 2759/4885KMT2A 4181/4885CYP3A4 4854/4885 |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | NR3C1, RXFP3, NR2E3 | MEN1 2581/4885KMT2A 3049/4885CYP3A4 1385/4885 |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | MCL1, HNF4A, THPO | MEN1 845/4885KMT2A 1448/4885CYP3A4 4586/4885 |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | RXFP3, NR3C1, NR2E3 | MEN1 2361/4885KMT2A 3224/4885CYP3A4 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.